Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for patients who have a prescription for the medication but no insurance coverage ...

Hims & Hers Health’s stock booked record losses Monday after Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ...

The calming in the oil market came as several analysts said Iran would likely refrain from closing the waterway. Iran itself ...

U.S. stocks are drifting, and oil prices are flip-flopping following the United States’ bunker-busting entry into Israel’s ...

Stocks jumped and oil prices tumbled Monday as Iran's retaliation for the U.S. bombing of the country's nuclear facilities resulted in no casualties or significant damage, raising hopes that the ...

Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Hims & Hers Health, Inc. (NYSE: HIMS) for potential violations of the federal securities laws.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The fortune of the San Francisco-based telehealth company’s cofounder and chief executive, Andrew Dudum, crumbled by more ...

Shares of Hims & Hers Health plunged by more than 30% after Danish weight-control drug maker Novo Nordisk abruptly pulled out of a partnership with the telehealth firm on the distribution of Wegovy.

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

The companies engaged in an increasingly heated war of words on Monday following the drugmaker's decision to end a collaboration.